Health & Medicine | Aug 16, 2026 | 9 min read | By Bryan White

Inside mFlusiva: The FDA's First mRNA Flu Vaccine Explained

Public Health * Vaccines * Immunology

Introduction: Modernizing Seasonal Influenza Immunization

Seasonal influenza remains a formidable public health burden, driving hundreds of thousands of hospitalizations and tens of thousands of deaths annually across the United States[1]. Epidemiological surveillance demonstrates that adults aged 65 and older bear the brunt of severe morbidity, accounting for roughly 57 percent of influenza-related hospitalizations and 71 to 85 percent of seasonal influenza mortality[2]. For decades, global influenza vaccine production has relied predominantly on propagating seed viruses in embryonated chicken eggs or mammalian cell cultures -- a workflow requiring a six-month manufacturing lead time that forces strain selection months ahead of the winter epidemic wave and leaves populations vulnerable to late-season antigenic drift[2][3][7].

On August 5, 2026, the U.S. Food and Drug Administration (FDA) approved mFlusiva (developed by Moderna as mRNA-1010), the first messenger RNA (mRNA) seasonal influenza vaccine authorized in the United States[1]. Indicated for adults aged 50 and older, mFlusiva leverages lipid nanoparticle (LNP) delivery to compress manufacturing timelines from six months to roughly eight to twelve weeks while eliminating avian egg-adaptive antigenic distortions[1][2].

The Structural Biology of Egg Adaptation vs. Synthetic mRNA

A critical vulnerability of conventional egg-based influenza vaccines is host-selected structural distortion of the viral hemagglutinin (HA) surface glycoprotein[7]. Human influenza viruses -- most notably A/H3N2 subtypes -- preferentially bind human upper-respiratory -2,6-linked sialic acid receptors. When passaged in avian allantoic cells within embryonated eggs, selective pressure favors viral variants bearing receptor-binding-site substitutions that enhance affinity for avian -2,3-linked sialic acids[12].

Because the HA receptor-binding pocket overlaps major antigenic epitopes, egg-adaptive substitutions such as L194P -- a replacement of leucine with proline at amino acid position 194 -- alter the three-dimensional conformation of the globular head domain[12][13]. Furthermore, epistasis among prevalent H3N2 residues such as T160 and N190 restricts L194P while channeling adaptation toward alternative substitutions like G186V[12]. When immunized with egg-adapted HA, human B cells generate neutralizing antibodies tailored to an avian-selected conformation that exhibits markedly reduced neutralization potency against circulating wild-type human H3N2 viruses[12][13]. By contrast, mFlusiva delivers synthetic mRNA transcripts that direct host cells to synthesize wild-type HA proteins matching circulating human strains with exact sequence fidelity[2][8].

Molecular Composition and SM-102 Lipid Nanoparticle Architecture

The 2026-2027 trivalent formulation of mFlusiva is a preservative-, antibiotic-, and egg-free sterile suspension administered as a single 0.38 mL intramuscular dose containing 37.5 g of nucleoside-modified mRNA (12.5 g per strain)[4][10]. Each transcript encodes the full-length membrane-bound hemagglutinin of one WHO/FDA-recommended seasonal strain: A/Missouri/11/2025 (H1N1)pdm09-like virus, A/Michigan/105/2025 (H3N2)-like virus, and B/Pennsylvania/19/2025 (B/Victoria lineage)-like virus[4][10].

To protect the mRNA cargo from extracellular ribonuclease degradation and mediate cellular uptake via endocytosis, each 0.38 mL dose encapsulates the transcripts within 0.759 mg of lipids formulated by microfluidic ethanol-aqueous mixing at a 50:10:38.5:1.5 molar ratio[4][8][11]:

* Ionizable Cationic Lipid (SM-102, 50 mol%): Remains neutral at physiological pH to minimize systemic toxicity, but protonates within the acidifying endosome, disrupting the anionic endosomal membrane to release mRNA into the cytosol before lysosomal degradation[5][11].

* Helper Phospholipid (DSPC, 10 mol%): 1,2-distearoyl-sn-glycero-3-phosphocholine stabilizes the nanoparticle lipid bilayer architecture[4].

* Cholesterol (38.5 mol%): Fills inter-lipid packing voids, regulating membrane fluidity and preventing premature payload leakage[4].

* PEGylated Lipid (PEG-2000-DMG, 1.5 mol%): Provides a hydrophilic steric shell that prevents nanoparticle aggregation and premature phagocytic clearance, buffered in tromethamine/sucrose for 2-8 deg C stability[4].

Immunological Mechanisms: Stalk-Reactive Antibodies and T-Cell Synergy

Following intramuscular injection and LNP uptake by local myocytes and antigen-presenting cells (dendritic cells and macrophages), ribosomal translation expresses native homotrimeric HA spikes on the host cell membrane[4]. Whereas conventional split-virion vaccines primarily elicit antibodies targeting the hypervariable globular head domain (HA1 antigenic sites Sb, Sa, Cb, Ca1, and Ca2), native membrane-anchored trimer presentation in mRNA vaccinees also boosts cross-reactive antibodies against the conserved hemagglutinin stalk domain (HA2), impeding viral-endosomal membrane fusion across divergent Group 1 and Group 2 strains (though stalk titers remain attenuated by immunosenescence in octogenarians)[14].

Crucially, unlike exogenous inactivated protein vaccines that poorly access cytosolic processing pathways, endogenously translated HA is cleaved by the proteasome and loaded onto Major Histocompatibility Complex (MHC) Class I molecules alongside MHC Class II presentation[15][17]. Clinical profiling demonstrates that mRNA-1010 induces polyfunctional CD4+ T-helper 1 (Th1) cells expressing the T-bet transcription factor and secreting interferon-gamma (IFN-), germinal-center T follicular helper (Tfh, Bcl-6+) cells that drive B-cell affinity maturation, upper-respiratory tissue-resident memory (TRM) cells, and cytotoxic CD8+ T

cells[15][16][18]. Subsequent IFN- -mediated downregulation of the IL-7 receptor tempers effector CD8+ expansion to prevent pulmonary immunopathology while preserving a durable cross-reactive memory T-cell pool[17][19].

Clinical Efficacy (FLUENT Trial), Reactogenicity, and Regulatory Pathway

After early Phase 3 candidates (P301/P302) met superiority/non-inferiority hemagglutination inhibition (HAI) endpoints for Influenza A (H1N1, H3N2) but underperformed against Influenza B lineages, Moderna reformulated mRNA-1010 for the Phase 3 P303 (IGNITE) trial, achieving superior geometric mean titers and seroconversion across all strains[8][20]. Pivotal clinical efficacy was established in the Phase 3 FLUENT trial (P304; NCT06602024), a randomized, observer-blind, active-controlled study enrolling 40,805 adults aged 50 years across 301 sites in 11 Northern Hemisphere countries during the 2024-2025 season[7][9].

The primary endpoint measured relative vaccine efficacy (rVE) against reverse-transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) compared with a licensed standard-dose comparator[7]. Confirmed ILI occurred in 2.0% of mFlusiva recipients (411/20,179) versus 2.8% of comparator recipients (557/20,124), yielding an overall rVE of 26.6% (95% CI: 16.7%-35.4%), an rVE of 23.5% under the modified CDC ILI definition, and an exploratory rVE of 47.9% against severe outcomes (urgent care, emergency admission, or hospitalization)[6][7].

| Efficacy Subgroup / Strain | | Relative Vaccine Efficacy (rVE) | | 95% Confidence Interval |

| Overall Population (50 years) | | 26.6% | | 16.7% to 35.4% |

| Age: 50 through 64 years | | 26.1% | | 12.3% to 37.7% |

| Age: 65 years and older | | 27.4% | | 12.1% to 40.0% |

| Age: 65 through 74 years | | 28.0% | | 10.4% to 42.2% |

| Age: 75 years and older | | 25.3% | | -10.4% to 49.5% |

| Strain: A/H1N1 | | 29.6% | | Point estimate reported |

| Strain: A/H3N2 | | 22.2% | | Point estimate reported |

| Strain: B/Victoria | | 29.1% | | Point estimate reported |

Across safety cohorts exceeding 14,000 participants, mFlusiva exhibited higher transient Grade 1-2 reactogenicity (median onset 2 days, duration 1-2 days) than standard-dose inactivated vaccines, but comparable serious adverse event rates (2.2% vs. 1.9%) and zero cases of vaccine-associated myocarditis or pericarditis within the 42-day post-vaccination window[4][6][7].

| Solicited Adverse Reaction (Days 1-7, Ages 50-64) | | mFlusiva Incidence (%) | | Standard-Dose Comparator Incidence (%) |

| Local: Injection-site pain | | 65.8% | | 29.8% |

| Local: Axillary swelling/tenderness | | 20.3% | | Not reported |

| Systemic: Fatigue | | 45.1% | | 20.3% |

| Systemic: Headache | | 37.8% | | 18.0% |

| Systemic: Myalgia (Muscle ache) | | 35.4% | | 11.6% |

| Systemic: Arthralgia / Chills | | 31.5% / 27.5% | | Not reported |

Regulatory review navigated an early-2026 CBER Refusal-to-File (RTF) dispute over the use of a standard-dose comparator rather than a high-dose senior comparator in the 65 FLUENT cohort[1][2][21]. Following inclusion of the P303 IGNITE high-dose comparator immunogenicity dataset and a unanimous 9-0 endorsement by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) in June 2026, the FDA granted bifurcated licensure on August 5, 2026: traditional full approval for adults aged 50-64 and accelerated approval for adults aged 65 (subject to a 400,000-participant postmarketing confirmatory trial against a high-dose comparator)[1][3][6].

Conclusion: Combination Vaccines and Pandemic Biosecurity

The licensure of mFlusiva validates synthetic LNP-mRNA vaccinology for seasonal influenza, eliminating egg-adaptive mutations such as L194P while delivering a 26.6% relative efficacy advantage over standard-dose vaccines[1][7][12]. Moreover, mFlusiva establishes the clinical foundation for multicomponent respiratory immunizations such as Moderna's Phase 3 mRNA-1083 candidate (combining mRNA-1010 with next-generation SARS-CoV-2 vaccine mRNA-1283), which achieved superior geometric mean ratios against Fluzone HD and Spikevax in adults aged 65 (1.155 for H1N1, 1.063 for H3N2, 1.118 for B/Victoria, and 1.641 for Omicron XBB.1.5) even as Moderna withdrew its initial U.S. BLA pending supplemental Phase 3 influenza efficacy data while advancing international filings, and provides rapid-response manufacturing capacity against future zoonotic H5 or H7 avian influenza pandemics[1][22].

Updates... (Nov 21, 2026): While standalone mFlusiva (mRNA-1010) entered the 2026-2027 U.S. respiratory season following its August 5, 2026 FDA licensure, Moderna previously withdrew its U.S. BLA for the combination influenza-COVID-19 candidate mRNA-1083 after the FDA requested additional Phase 3 influenza efficacy data, even as mRNA-1083 advanced through international approvals (including as mCOFLU in Canada). Additionally, replaced clinic-blog and preprint references with the official FDA MFLUSIVA licensure record and the peer-reviewed PLOS Pathogens publication (Liang et al., Sep 26, 2022), and standardized exact publication dates across References 1-22 (including Wu et al., May 28, 2019 and Prabhu et al., Sep 11, 2013).

References & Primary Sources

* [1] BioPharma Dive (Aug 6, 2026). FDA approves Moderna's mRNA flu vaccine. -- https://www.biopharmadive.com/news/moderna-fda-approve-mflusiva-seasonal-influenza/826864/

* [2] AJMC (Aug 6, 2026). FDA Approves Moderna's mRNA Flu Vaccine After Phase 3 Success. -- https://www.ajmc.com/view/fda-approves-moderna-s-mrna-flu-vaccine-after-phase-3-success

* [3] The Associated Press (Jun 18, 2026). FDA panel backs first-of-its-kind flu vaccine using mRNA technology. -- https://www.ap.org/news-highlights/spotlights/2026/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology/

* [4] U.S. Food and Drug Administration (FDA) (Aug 5, 2026). Package Insert and Information for Patients - MFLUSIVA. -- https://www.fda.gov/media/194120/download

* [5] U.S. Food and Drug Administration (FDA) (Aug 5, 2026). Information For Recipients and Caregivers - MFLUSIVA. -- https://www.fda.gov/media/194126/download?attachment

* [6] U.S. Food and Drug Administration (FDA) (Aug 5, 2026). FDA Review of Efficacy, Immunogenicity, and Safety of mFlusiva. -- https://www.fda.gov/media/193214/download

* [7] Leroux-Roels, I., Huang, G., Ferguson, M., et al. (May 7, 2026). Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. New England Journal of Medicine. -- https://doi.org/10.1056/NEJMoa2516491

* [8] Kandinov, B., Soens, M., Huang, W., et al. (Apr 2, 2025). An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. Human Vaccines & Immunotherapeutics. -- https://doi.org/10.1080/21645515.2025.2484088

* [9] ClinicalTrials.gov (Sep 16, 2026). NCT06602024: A Study of mRNA-1010 Compared With a Licensed Seasonal Influenza Vaccine in Adults (FLUENT). -- https://clinicaltrials.gov/study/NCT06602024

* [10] U.S. Food and Drug Administration (FDA) (Aug 5, 2026; updated Sep 2, 2026). MFLUSIVA (Influenza Vaccine, mRNA) -- STN 125869/0. -- https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva

* [11] MedChemExpress (2025). SM-102 (GMP) Product Data Sheet. -- https://file.medchemexpress.com/batch_PDF/HY-134541G/SM-102-GMP-DataSheet-MedChemExpress.pdf

* [12] Liang, W., Tan, T. J. C., Wang, Y., Lv, H., et al. (Sep 26, 2022). Egg-adaptive mutations of human influenza H3N2 virus are contingent on natural evolution. PLOS Pathogens, 18(9), e1010875. -- https://doi.org/10.1371/journal.ppat.1010875

* [13] Wu, N. C., Lv, H., Thompson, A. J., et al. (May 28, 2019). Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility. Cell Host & Microbe, 25(6), 836-844. -- https://doi.org/10.1016/j.chom.2019.04.013

* [14] S nchez-de Prada, L., Sanz-Mu oz, I., Eiros, J. M., et al. (May 29, 2023). Group 1 and group 2 hemagglutinin stalk antibody response according to age. Frontiers in Immunology, 14, 1194073. -- https://doi.org/10.3389/fimmu.2023.1194073

* [15] Finn, C. M., & McKinstry, K. K. (Apr 5, 2024). Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus. Cells, 13(7), 639. -- https://doi.org/10.3390/cells13070639

* [16] Hornick, E. E., Zacharias, Z. R., & Legge, K. L. (Oct 2, 2019). Kinetics and Phenotype of the CD4 T Cell Response to Influenza Virus Infections. Frontiers in

Immunology, 10, 2351. -- https://doi.org/10.3389/fimmu.2019.02351

* [17] van de Ven, K., Lanfermeijer, J., van Dijken, H., et al. (Dec 16, 2022). A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Science Advances, 8(50), eadc9937. -- https://doi.org/10.1126/sciadv.adc9937

* [18] Henry, C., Makrinos, D., Liu, R., et al. (Jan 14, 2026). An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial. npj Vaccines. -- https://doi.org/10.1038/s41541-026-01370-7

* [19] Prabhu, N., Ho, A. W. S., Wong, K. H., et al. (Sep 11, 2013). Gamma Interferon Regulates Contraction of the Influenza Virus-Specific CD8 T Cell Response and Limits the Size of the Memory Population. Journal of Virology, 87(23), 12510-12522. -- https://doi.org/10.1128/JVI.01776-13

* [20] FirstWord Pharma (Feb 16, 2023). Moderna's mRNA-1010 seasonal flu vaccine yields mixed results. -- https://firstwordpharma.com/story/5707315

* [21] FirstWord Pharma (Aug 6, 2026). US approves Moderna's mRNA flu vaccine after FDA review battle. -- https://firstwordpharma.com/story/7821538

* [22] Rudman Spergel, A. K., Wu, I., Deng, W., et al. (Jun 10, 2025). Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults 50 Years: A Randomized Clinical Trial. JAMA, 333(22), 1977-1987. -- https://doi.org/10.1001/jama.2025.5646